Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-11-04 EST			5-day change	1st Jan Change
9.340 ^USD	-2.61%		+3.78%	+14.18%

10-27	Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating	MT
10-23	ORIC Pharmaceuticals, Inc. - Special Call

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

f0c7517f73d592cd.b0l7l6VReJoLQ3AIArwNbUB-2Qh-4MRYk4P1IKMBWm4.IT0W9cMHEPNiDCJaevNiVRRGsEsSg54J6e6CRspIIhZdKyqi0Rsg8GAMIQ~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

10-27	Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating	MT
10-05	Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target	MT
09-23	BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target	MT
04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
01-07	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
11-14	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
25-05-06	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
24-10-31	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
24-10-31	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
24-09-06	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
24-08-13	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
24-03-27	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
24-03-21	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
24-03-12	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
24-03-01	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
24-02-26	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
23-12-13	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
23-12-12	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
23-10-26	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
23-10-24	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23-10-23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
23-09-22	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
23-08-16	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
23-08-15	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
23-05-10	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+126.43%
	WUXI APPTEC CO., LTD.					+49.57%
	LONZA GROUP AG					+8.14%
	ARGENX SE					+26.88%
	IQVIA HOLDINGS INC.					+18.77%
	BEONE MEDICINES AG					+23.26%
	REVOLUTION MEDICINES, INC.					+33.27%
	GENMAB A/S					+7.64%
	CELLTRION, INC.					+42.53%
	INSMED INCORPORATED					+85.93%
	Average					+42.24%
	Weighted average by Cap.					+30.56%